Abstracts tagged "flow cytometry and systemic lupus erythematosus (SLE)"

Abstract Number: 2691 • 2014 ACR/ARHP Annual Meeting
A Novel CD123^–CD11c^– Dendritic Cell Subset Increased in Relation to Disease Activity in Patients with Systemic Lupus Erythematosus
Satoshi Kubo¹, Shingo Nakayamada¹, Naoki Yunoue¹, Maiko Yoshikawa¹, Kunihiro Yamaoka¹ and Yoshiya Tanaka², ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by overproduction of autoantibodies by B cells and breaking self-tolerance of T cells and dendritic…
Abstract Number: 1623 • 2014 ACR/ARHP Annual Meeting
Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus
Julie Ducreux¹, Séverine Nieuwland², Frédéric A. Houssiau¹ and Bernard R. Lauwerys¹, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Institut de Recherche Expérimentale et Clinique, Pôle de pathologies rhumatismales, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: systemic lupus erythematosus (SLE) is characterized by a break of tolerance to autoantigens, and polyclonal activation of B cells. We performed multicolor flow cytometry…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].